2024-01-29 08:50:04 ET
More on CytoDyn
Read the full article on Seeking Alpha
For further details see:
CytoDyn appoints Jacob Lalezari as CEO, Mitchell Cohen as interim CFO2024-01-29 08:50:04 ET
Read the full article on Seeking Alpha
For further details see:
CytoDyn appoints Jacob Lalezari as CEO, Mitchell Cohen as interim CFOMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
TAAT Global Alternatives Inc. (TOBAF) is expected to report for quarter end 2024-01-31 ABCO Energy (ABCE) is expected to report for quarter end 2023-12-31 GameSquare Holdings Inc. (GAME) is expected to report $-0.26 for Q1 2023 Skillsoft Corp. Class A (SKIL) is expected to report $-3....
QUADIENT S.A ADR (NPACY) is expected to report for quarter end 2024-01-31 Jeffs' Brands Ltd (JFBR) is expected to report for quarter end 2023-12-31 Avid Bioservices Inc. (CDMO) is expected to report $0.02 for Q3 2024 TAAT Global Alternatives Inc. (TOBAF) is expected to report for quar...
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications...